DERMATA THERAPEUTICS, INC. Total Liabilities and Equity
DERMATA THERAPEUTICS, INC. (DRMA) had Total Liabilities and Equity of $5.32 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-11
- 2026-06-30: Liabilities and Equity $5.32M.
- 2026-03-31: Liabilities and Equity $7.47M.
- 2025-12-31: Liabilities and Equity $7.86M.
- 2025-09-30: Liabilities and Equity $5.07M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $5.32M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $7.47M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $7.86M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $5.07M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $6.64M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $10.01M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $3.53M 10-K · filed 2026-03-26 |
| 2024-09-30 | $6.69M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $5.24M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $5.18M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $7.98M 10-K · filed 2025-03-17 |
| 2023-09-30 | $7.32M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $8.71M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $9.30M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $6.94M 10-K · filed 2024-03-21 |
| 2022-09-30 | $8.97M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $11.03M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $9.04M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $11.62M 10-K · filed 2023-02-21 |
| 2021-09-30 | $13.69M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $1.14M 10-Q · filed 2021-09-27 |
| 2020-12-31 | $605.45K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |